C-terminal alpha-1-antitrypsin peptides as novel predictor of hospital mortality in critically ill COVID-19 patients

Franziska Scherr,Daniel Schwarzkopf,Daniel Thomas-Rüddel,Michael Bauer,Michael Kiehntopf

DOI: https://doi.org/10.1515/cclm-2024-0920

2024-08-19

Clinical Chemistry and Laboratory Medicine (CCLM)

Abstract:To the Editor, The COVID-19 pandemic caused by the SARS-CoV-2 virus has resulted in over 771 million confirmed cases and more than 6 million deaths worldwide by the end of 2023 [1]. While the pandemic has since slowed down due to vaccination and natural immunity, understanding the molecular mechanisms behind infection and disease progression remains crucial not only for the remaining COVID-19 patients but also to further our understanding of other severe infectious diseases like sepsis. One major shortcoming during the COVID-19 pandemic was the prediction of disease severity in SARS-CoV-2 positive patients. While well-known risk factors like age, BMI and pre-existing conditions were also associated with COVID-19 disease severity, also many young and seemingly healthy people developed severe conditions [2]. Furthermore, classic laboratory parameters of inflammation and disease severity like interleukin-6 (IL-6) and procalcitonin (PCT) were of limited value. Treatment with corticosteroids like dexamethasone, which is standard of care for ventilated COVID-19 patients, severely downregulates these two markers [3]. To overcome these shortcomings, we evaluated the prognostic potential of C-terminal alpha-1-antitrypsin peptides (CAAPs). These peptides are proteolytic cleavage products of alpha-1-antitrypsin (AAT), an important immunomodulatory protease inhibitor. As acute phase protein, AAT is highly upregulated during inflammation and has multifaceted roles in the innate immune response [4]. Several endogenous as well as pathogen-derived proteases have been described to interact with and cleave AAT, resulting in the release of CAAPs. Importantly, CAAPs have already been found in several infectious and inflammatory conditions. C42 has been previously proposed as sepsis marker, and we already showed in a pilot study that both C36 and C42 are found to be elevated in the plasma of COVID-19 patients [5, 6]. In this work, we measured CAAPs plasma concentrations in 84 patients with severe COVID-19 on day one to four after their admission to the ICU. In our cohort, we observed a mortality rate of 26.2 % (Table 1). Non-survivors were older than survivors (median 74.5 vs. 63 years), while BMI and sex ratio did not differ significantly between the groups. In accordance with disease severity, non-survivors had higher SOFA scores and needed ECMO, dialysis and mechanical ventilation interventions more often than survivors. We also determined the levels of IL-6 and PCT as gold standard and found them significantly elevated in non-survivors (42.1 vs. 18.5 ng/L and 0.29 vs. 0.14 μg/L, respectively). These concentrations are in accordance with previously published reports, except for the PCT levels in non-survivors, which were usually higher than in our cohort. Characteristics at sampling timepoint (day 1–4 after ICU admission) and pre-existing conditions of patients who later died in hospital or survived and were discharged. a Median (IQR); n (%), b Wilcoxon rank sum test; Pearson's Chi-squared test; BMI, body mass index; COPD, chronic obstructive pulmonary disease; SOFA, sequential organ failure assessment score; ECMO, Extracorporeal membrane oxygenation support; PCT, procalcitonin; IL-6, interleukin-6, f, female; m, male. Regarding the C-terminal AAT peptides, we observed a trend of elevated plasma concentrations in non-survivors, with the exception of one peptide, C44, which showed an opposite trend. In addition, we calculated CAAP/IL-6 ratios analogous to Philippe et al. investigating the AAT/IL-6 ratio as a measure of immune system deregulation [7]. Ratios of C42, C43 and C44 with IL-6 were significantly decreased in non-survivors (Table 1). We further confirmed that those ratios offer additive predictive value regarding hospital mortality compared to IL-6 or PCT alone. Logistic regression models using IL-6 or PCT as predictors performed better regarding their akaike information criterion (AIC) and McFadden's R 2 when C36, C40, C42, C44 or any CAAP/IL-6 ratio was added (Supplement Table 1). Lastly, we identified the most informative predictors of hospital mortality among CAAPs and CAAP/IL-6 ratios by logistic regression. A forward and backward selection based on the AIC was performed using the stepAIC function of the MASS package in R. The final model consisted of C40 and C44/IL-6 as predictors and was compared to models using only IL-6 or PCT as predictors (Figure 1, Supplement Table 2). We trained all models in a random 70 % split of the cohort (training set) and evaluated them in the remaining 30 % (test set). In the training set, best performance characterized by highest area under the receiver operating characteristic curve (AUC) was achieved by our model (AUC=0.758), followed by PCT (AUC=0.742) and IL-6 (AUC=0.699). Next, we calculated optimal cutoffs for prediction of hospital mortality as determined by Youden's index for -Abstract Truncated-

medical laboratory technology